The suppression of ventricular fibrillation by antidysrhythmic drugs is well correlated with their ability to block potassium channels in nerve and cardiac membranes. Blockade of potassium channels reduces electrical inhomogeneities in action potential and conduction parameters that lead to ventricular fibrillation. These actions tend to effectively decrease the electrical size of the heart, which suggests a mechanism for antifibrillatory drug action. The receptor sites for antifibrillatory drug action (IK blockade) appear to be on the outside of the cardiac membrane whereas receptors for antiarrhythmic drug action (INa blockade) appear to be on the inside of the cardiac membrane.
ABSTRACT
The suppression of ventricular fibrillation by antidysrhythmic drugs is well correlated with their ability to block potassium channels in nerve and cardiac membranes. Blockade of potassium channels reduces electrical inhomogeneities in action potential and conduction parameters that lead to ventricular fibrillation. These actions tend to effectively decrease the electrical size of the heart, which suggests a mechanism for antifibrillatory drug action. The receptor sites for antifibrillatory drug action (IK blockade) appear to be on the outside of the cardiac membrane whereas receptors for antiarrhythmic drug action (INa blockade) appear to be on the inside of the cardiac membrane.
Ventricular fibrillation, the major cause of sudden cardiac death, has long been regarded as an extension of less lethal ventricular arrhythmias that could be prevented by class 1 antiarrhythmic drugs (1) . However, almost every controlled study has failed to show a reduction in the incidence of ventricular fibrillation by prophylactic administration of lidocaine even when arrhythmias per se were suppressed (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . In contrast, ventricular fibrillation can be suppressed by bretylium tosylate and its pharmacologic analog, bethanidine sulphate (2, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . Both drugs (termed class 3) increase ventricular fibrillation threshold manyfold, facilitate electrical defibrillation, and induce episodes of pharmacologic (spontaneous) defibrillation under conditions where it does not normally occur (refs. 2, 12, 21-31 and Fig. la) . Class 1 antiarrhythmic drugs such as lidocaine and procainamide do not have comparable antifibrillatory effects (12, 30, 31) . These drugs also differ from bretylium and bethanidine in their effects on cardiac action potential parameters (33) (34) (35) (36) (37) , which further indicates that antifibrillatory and antiarrhythmic drug actions are not directly related. This report demonstrates that these differing drug actions are correlated with differences in the blockade of membrane ionic currents. Preliminary reports of these experiments have been published (38, 39, 44) .
METHODS
Experiments were performed on internally perfused squid giant axons, chicken embryonic heart cell aggregates, and anesthesized mongrel dog hearts by using standard techniques for each preparation (12, (40) (41) (42) (43) .
Squid Axon. Membrane currents were measured by axial wire voltage-clamp technique in squid axon before and after addition of test drugs to either the internal or the external bathing medium. The voltage-clamp protocol consisted of serial depolarizations of membrane potential lasting several milliseconds from a holding potential of -80 mV (inside negative) to -50, -40, -30, ... +30 mV with a rest interval of 5 sec between each step. Drugs tested were bretylium, bethanidine, lidocaine, procainamide, meobentine, and guanethidine.
Chicken Heart Cells. Voltage-clamp measurements were performed on embryonic chicken heart cell aggregates before and after addition of bretylium to the external medium. Chicken hearts were dissected from 7-to 12-day-old embryos and dissociated into their component cells with trypsin (0.05%). (12, 23, 29) . Drugs used were bretylium, bethanidine, lidocaine, procainamide, meobentine, guanethidine, tetraethylammonium, tetramethylammonium, 4-aminopyridine, and cesium. The doses are given in Fig. 1 and Table 1 .
RESULTS
In the dog heart bretylium and bethanidine each caused a significant sustained increase in VFT. In contrast, lidocaine typically induced a small transient increase in VFT and procainamide had virtually no effect (Fig. la) .
Squid Axon. The effects of these drugs on voltage-clamped squid axons are shown in Fig. 2 . In each case depolarizing voltage steps elicited an inward sodium current ('Na) and an outward potassium current (IK), similar to the original results of Hodgkin and Huxley (45) . Bretylium, bethanidine, Abbreviations: I, current; VFT, ventricular fibrillation threshold; APD, action potential duration.
2223
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (a) Representative effect of antidysrhythmic drugs on VFT in dog heart. Control threshold was determined for each animal at zero time. Drugs were administered intravenously shortly thereafter. Drug dosages based on the upper limits that are used clinically were as follows: procainamide, 9.4 mg/kg; lidocaine, 7 mg/kg; bretylium, 20 mg/kg; bethanidine, 20 mg/kg. Additional drug dosages were administered at approximately the 3-hr mark in the bretylium and bethanidine experiments. (b) Representative effect of standard potassium channel blockers on fibrillation threshold in dog heart by using the same experimental protocol as in a. Note that tetraethylammonium (TEA), tetramethylammonium (TMA), 4-aminopyridine (4-AP), and cesium (Cs) increased fibrillation threshold to 100 mA, the maximum output of our current generator.
lidocaine, and procainamide partially blocked both the INa and IK current components when the drugs were added to the internal perfusing solution (Fig. 2, Table 1 ). The effects of these drugs on IK are further illustrated in Fig. 3 along with the effects of tetraethylammonium, which is a standard potassium channel blocker. Tetrodotoxin was added to the external solution in these experiments to block the INa component. These results demonstrate that equimolar concentrations (5 mM) of bretylium and bethanidine produce a significantly greater blockade of IK than either lidocaine or procainamide.
Fibrillation Threshold. To further relate our observations in squid axon to dog heart, we tested the effects of tetraethylammonium (3 dogs), 4-aminopyridine (3 dogs), cesium (2 dogs), and tetramethylammonium (2 dogs) on fibrillation threshold. These diverse chemical agents, all of which are known blockers of potassium current in nerve and cardiac membranes (46) (47) (48) (49) (50) (51) (52) , significantly increased VFT in dog hearts (Fig. lb) .
Adrenergic Blockade. Bretylium inhibits transmitter release from sympathetic neurons, which may suggest that adrenergic blockade is the mechanism for its antifibrillatory effect (34) . Our results with guanethidine and meobentine argue against this view. Guanethidine, which has the same antiadrenergic effect as bretylium, has little antifibrillatory effect (12, 53) . Furthermore, meobentine, the 0-methyl analog of bethanidine, has no antiadrenergic action but it increases VFT significantly (ref. 54 and Table 1 ) and also induces pharmacologic defibrillation (unpublished observation, M.B.B.). The results with both drugs are well correlated with their effects on IK in squid axons (Table 1) . These experiments further indicate that blockade of IK underlies antifibrillatory drug action. Cardiac Cells. To test our prediction that bretylium would also block IK in cardiac cells, voltage-clamp studies on chicken embryonic heart cell aggregates were carried out. When bretylium (1 mM) was placed in the external medium, outward current was significantly reduced as shown by the reduction in IK at the end of the voltage steps (Fig. 4) . In seven preparations bretylium consistently blocked both a time-dependent outward current and a time-independent (background) component. Blockade of the time-dependent outward current is especially evident by the reduction of the tail current amplitude (Fig. 4, Inset) upon return to the holding potential (-55 mV). Blockade of the background component is apparent in the reduction of the initial current jump immediately following the voltage step (Fig. 4, Inset) . The time-dependent component has been demonstrated to be a potassium ion-selective current (A.S. and J.R.C., unpublished observations). The time-independent, or background component, is also carried at least partly by potassium ions (A.S. and J.R.C., unpublished observations).
Site of Action. Our data provide some insight into which side of the membrane the receptors are located for drugs that block sodium and potassium channels. Lidocaine and procainamide partially blocked INa and IK in squid axons when the drugs were added to either the internal or external solution (Figs. 2 and 5 ). Bretylium and bethanidine (Fig. 5) had no effects on either current component when they were added to the external solution in contrast to their strong effects when they were added to the internal solution (Figs.  2 and 3) . These results indicate that the receptor sites for drug blockade of IK and INa in squid axons are on the internal side of the axonal membrane. The differing actions of external lidocaine and bretylium can be attributed to differing lipid solubilities of these agents. Lidocaine is able to cross the squid axon membrane to reach the sites for blockade of 'K and INa in contrast to bretylium, a quaternary ammonium compound, with poor lipid solubility. The lack of effect of external bretylium on INa in squid axons is consistent with its Proc. Natl. Acad. Sci failure to decrease upstroke velocity (Vmax) of the normal cardiac action potential (33) (34) (35) , which suggests that bretylium is also unable to cross the cardiac membrane. The lack of effect of external bretylium and bethanidine on IK in squid axons is attributable to the lack of an external receptor for most potassium channel blockers in this preparation, in contrast to other nerve and cardiac preparations where it is present (46, 47) . Our results on chicken heart cell aggregates (Fig. 4) [55] [56] [57] [58] [59] . These effects can cause ventricular fibrillation when the disruption of normal ion transport causes action potential and conduction inhomogeneities that critically desynchronize normal excitation and contraction coupling over a sufficient mass of myocardium (2) .
It has long been known that sustained fibrillation is related to the absolute size of the heart (32). For example, ventricular fibrillation usually terminates spontaneously in the hearts of small animals (cat, rat, and rabbit). In large hearts (dog, beef, and man) ventricular fibrillation persists until death unless terminated by electrical countershock, because the large number of cells and long conduction paths make spontaneous electrical and contractile resynchronization improbable. Similarly, the ischemic or infarcted myocardium can become effectively "enlarged" electrophysiologically because of abnormal and aberrant conduction characteristics caused by action potential inhomogeneities. Bretylium has been shown to decrease such inhomogeneities in conduction times between normal and ischemic myocardium (58) . Thus, the large heart or the ischemically injured h~art may take on some characteristics of the small heart following administration of bretylium, bethanidine, or meobentine, as indicated by episodes of pharmacologic defibrillation and an increase in VFT to supernormal levels.
The blockade of IK explains the most consistent electrophysiologic action of bretylium, which is to increase the action potential duration (APD) (33) (34) (35) . Bethanidine and meobentine have also been reported to have similar effects on APD in rat heart (37) . Moreover, clofilium, another class 3 antifibrillatory drug, has been reported to block IK in guinea pig heart cells (60) . Blockade of IK could exert an important antifibrillatory action by blocking an increase in potassium conductance (61) with shortening of APD that often immediately precedes the onset of fibrillation (61, 62) . In ischemic or infarcted myocardium, bretylium prolongs APD in both the uninvolved normal cells and in injured cells with abnormally shortened APD so that duration is prolonged about equally in both groups (63) . Since bretylium has little effect on APD in ischemic injured cells where it is already abnormally prolonged, the net effect is a reduction in the temporal and spatial disparity of APDs between normal and injured cells throughout the heart (33). Increased homogeneity of both APD and conduction parameters (58) would result in more synchronous and uniform coupling of excitation and contraction. These actions tend to effectively reduce the electrical size of the heart, which could explain the increased resistance to initiating and sustaining fibrillation induced by antifibrillatory drugs. Our results suggest that one important mechanism underlying this effect is the blockade of one or more potassium ion currents.
